Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

It is well established that the human brain exhibits regional variability in its vulnerability to Alzheimer's disease (AD) pathology. We set out to determine if this regional vulnerability is reflected in the expression pattern, or processing, of two key proteins involved in AD pathology, the β-amyloid precursor protein (APP) and tau, by immunoblotting. Our data demonstrate that APP processing and APP protein levels are not different between AD patients and healthy, age-matched subjects, but that levels of mature APP are greatly reduced in cerebellum compared to regions of the brain most vulnerable to AD, entorhinal cortex and hippocampus. In addition, protein levels of tau are significantly reduced in cerebellum compared to all other human brain regions examined. Unexpectedly, protein levels of glycogen synthase kinase 3 (GSK3), a major tau kinase, are at their lowest in hippocampus. The observations demonstrate that both mature APP as well as total APP and tau protein levels are greatly reduced in human cerebellum, a region of the human brain most resistant to AD pathology.

Original publication

DOI

10.1016/j.neulet.2010.08.088

Type

Journal article

Journal

Neurosci Lett

Publication Date

26/11/2010

Volume

485

Pages

162 - 166

Keywords

Actins, Aged, Aged, 80 and over, Alzheimer Disease, Amyloid beta-Protein Precursor, Brain Chemistry, Cerebellum, Diagnostic and Statistical Manual of Mental Disorders, Female, Glycogen Synthase Kinase 3, Hippocampus, Humans, Immunoprecipitation, Insulysin, Male, Nerve Degeneration, Neuropsychological Tests, tau Proteins